{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for teniposide in Standardized Name (approximate match)
Showing 1 - 5 of 5 results
4'-demethylepipodophyllotoxin (DMEP) belongs to the class of podophyllotoxin. Podophyllotoxin is a natural product from the roots and rhizomes
of Podophyllum species and binds at the colchicine site as a microtubule inhibitor. DMEP is an antimitotic agent which binds to monomeric tubulin, preventing microtubule polymerization. It can reduce the tumor formation and growth in a mouse skin carcinogenesis model. DMEP derivatives exert strong antitumor properties.
Status:
US Previously Marketed
Source:
VUMON by HQ SPECLT PHARMA
(1992)
Source URL:
First approved in 1992
Source:
VUMON by HQ SPECLT PHARMA
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Teniposide is an inhibitor of topoisomerase II with anti-cancer activity. The drug was approved by FDA under the name Vumon for the treatment of children with acute lymphoblastic leukemia.